| Title: | Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study |
| Journal: | The Lancet Regional Health - Europe |
| Published: | 22 Mar 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38549731/ |
| DOI: | https://doi.org/10.1016/j.lanepe.2024.100887 |
| URL: | http://dx.doi.org/10.1016/j.lanepe.2024.100887 |
Publication 10066
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Cardiovascular disease incidence and mortality have declined across developed economies and granular up-to-date cost-effectiveness evidence is required for treatments targeting large populations. To assess the health benefits and cost-effectiveness of standard and higher intensity statin therapy in the contemporary UK population 40-70 years old.</p>
Methods: A cardiovascular disease microsimulation model, developed using the Cholesterol Treatment Trialists' Collaboration data (117,896 participants; 5 years follow-up), and calibrated in the UK Biobank cohort (501,854 participants; 9 years follow-up), projected risks of myocardial infarction, stroke, coronary revascularization, diabetes, cancer and vascular and nonvascular death for all UK Biobank participants without and with statin treatment. Meta-analyses of trials and cohort studies informed statins' relative effects on cardiovascular events, incident diabetes, myopathy and rhabdomyolysis. UK healthcare perspective was taken (2020/2021 UK£) with costs per 28 tablets of £1.10 for standard (35%-45% LDL cholesterol (LDL-C) reduction) and £1.68 for higher intensity (≥45% LDL-C reduction) generic statin.</p>
Findings: Across categories by sex, age, LDL-C, and cardiovascular disease history/10-year cardiovascular risk, lifetime standard statin increased survival by 0.28-1.85 years (0.20-1.09 quality-adjusted life years (QALYs)), and higher intensity statin by further 0.06-0.40 years (0.03-0.20 QALYs) per person. Standard statin was cost-effective across all categories with incremental cost per QALY from £280 to £8530, with higher intensity statin cost-effective at higher cardiovascular risks and higher LDL-C levels. Stopping statin early reduced benefits and was not cost-effective.</p>
Interpretation: Lifetime low-cost statin therapy is cost-effective across all 40-70 years old in UK. Strengthening and widening statin treatment could cost-effectively improve population health.</p>
Funding: UK NIHR Health Technology Assessment Programme (17/140/02).</p>
14 Authors
- Borislava Mihaylova
- Runguo Wu
- Junwen Zhou
- Claire Williams
- Iryna Schlackow
- Jonathan Emberson
- Christina Reith
- Anthony Keech
- John Robson
- Richard Parnell
- Jane Armitage
- Alastair Gray
- John Simes
- Colin Baigent
1 Application
| Application ID | Title |
|---|---|
| 56757 | Developing chronic disease models to inform health policy and guide treatment decisions |
Enabling scientific discoveries that improve human health